Effect of Vit D therapy on anti-Mullerian hormone (AMH) level in women with infertility

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201604137917N2

Enrollment

Registered

2016-05-30

Start date

2015-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility associated with anovulation

Interventions

Mothers with Vit D deficiency, 50000 IU of Pearl of Vit D producted in Zahravi Pharmaceutical Company weekly for three months administered..

Treatment - Drugs

Mothers with Vit D deficiency, 50000 IU of Pearl of Vit D producted in Zahravi Pharmaceutical Company weekly for three months administered.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria : patients suffering infertility with insufficient Vit. D (lower than 30 ng/ml); Anti mullerian horman level less than 0.7 ng/ml. Exclusion criteria :Vit Duse contraindication; Vit D use during 4 months before study; use of OCP during 2 months before study; thyroid function disorder; hyper prolactinemia; diabetes melituse; cogenital adrenal hyperplasia; Use of drugs affect on adrenal and ovarian function and metabolism of carbohydrates and lipids; Pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Anti Mullerian Hormone Level. Timepoint: before and three months after intervention. Method of measurement: Hospital Labratoary.	—

Secondary

Measure	Time frame
Fertility. Timepoint: up to one year after intervention. Method of measurement: Birth Report of the participants.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Naderi, MD

Iran University of Medical Sciences

naderi_gyn@yahoo.com+98 21 8214 1201

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026